Application of bifidobacterium pseudolongum in preparation of composition for treating intestinal flora imbalance or intestinal inflammation
The composition prepared using Bifidobacterium pseudolongum regulates the balance of intestinal flora, solves the problem of regulating intestinal inflammatory diseases, significantly alleviates intestinal inflammation and related symptoms, and improves the intestinal health of animals.
Patent Information
- Application Number
- CN202410827334.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-25
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies are insufficient to effectively regulate the balance of gut microbiota and alleviate the symptoms of inflammatory bowel diseases, especially in animals such as dogs and cats, where antibiotic overuse increases the risk of inflammatory bowel diseases.
Compositions for treating intestinal flora imbalance or intestinal inflammation are prepared using Bifidobacterium pseudolongum, including fermented products, bacterial powder preparations, and dietary supplements. These compositions alleviate intestinal pathological symptoms and relieve inflammation by regulating the balance of intestinal flora.
Bifidobacterium pseudolongum can significantly regulate the gut microbiota, reduce intestinal inflammation, alleviate small intestinal tight junction damage, endoplasmic reticulum stress and abnormal smooth muscle contraction, reduce the expression of inflammatory factors, reduce cell death, and improve the gut health of animals.
Smart Images

Figure CN118924796A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to application of Bifidobacterium pseudolongum in preparing a composition for treating intestinal flora imbalance or intestinal inflammation. Background Art
[0002] The intestinal flora, also known as the intestinal microbiota or gut microbiome, is a key component of human health. The intestinal flora can help the animal body build and maintain a healthy immune system, train its immune system in the early years of the animal, and help distinguish between substances that are beneficial or harmful to the body. They establish defenses against pathogens by interacting with intestinal immune cells, maintain the intestinal barrier function, and prevent harmful substances and pathogens from entering the blood. The intestinal microbiota affects energy balance and nutrient metabolism. It is involved in the synthesis of vitamins (such as vitamin K and certain B vitamins) and essential amino acids. The intestinal flora is also called the second brain, which can affect mental health, including emotions and behavior, through the so-called "gut-brain axis". In addition, the metabolites of intestinal microorganisms can enter the liver through the portal vein and affect the occurrence and development of liver diseases. An imbalance in the intestinal flora is associated with the occurrence of many chronic diseases. Previous studies have shown that the intestinal flora plays an important role in regulating chronic diseases including inflammatory bowel disease, type II diabetes, cardiovascular disease, cancer, and neurodegenerative diseases. A disordered intestinal microbiota may cause the immune system to over- or under-react, triggering allergic reactions or autoimmune diseases.
[0003] Inflammatory bowel disease is a chronic intestinal disease that includes Crohn's disease and ulcerative colitis. Both can cause inflammation and discomfort in the intestine. Diarrhea and abdominal pain are the most common symptoms of inflammatory bowel disease, and in severe cases, bloody stools may occur. Inflammatory bowel disease can also cause loss of appetite, poor nutrient absorption, and even chronic diarrhea, which can lead to weight loss. Fever and fatigue are often present during active stages of the disease. Crohn's disease is characterized by the possibility of lesions occurring throughout the entire intestine, with a wide range of lesions. Crohn's disease lesions are often intermittent, with healthy and diseased tissue alternating. Crohn's disease often leads to intestinal perforation and fistula formation as it develops in animals. Ulcerative colitis is characterized by relatively small lesions that are limited to the colon, continuous lesions, and more common bleeding than Crohn's disease.
[0004] In the livestock industry, intestinal inflammatory diseases have a significant impact on animals such as dogs and cats. Its development is related to immune response. Although the specific cause is still unclear, studies have shown that the interaction between genetic factors and intestinal bacteria is crucial to the development of the disease. Due to the increasing abuse of antibiotics, there is a complex and important relationship between antibiotic abuse and the prevention and treatment of intestinal inflammatory diseases. The use of broad-spectrum antibiotics may increase the risk of new intestinal inflammatory diseases and their subtypes. The search for natural treatments for intestinal inflammatory diseases has become a research hotspot in recent years.
[0005] Therefore, the present invention provides the use of Bifidobacterium pseudolongum in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation. Bifidobacterium pseudolongum can regulate the balance of intestinal flora, while alleviating intestinal pathological symptoms and intestinal inflammation, and can be widely used in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation. Summary of the invention
[0006] The purpose of the present invention is to provide an application of Bifidobacterium pseudolongum in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation. Bifidobacterium pseudolongum can regulate the balance of intestinal flora, while alleviating intestinal pathological symptoms and intestinal inflammation, and can be widely used in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation.
[0007] To achieve the above object, the present invention provides the use of Bifidobacterium pseudolongum in preparing a composition for treating intestinal flora imbalance, which is used to prepare a composition for treating intestinal flora imbalance, and the composition includes a fermented product, a bacterial powder preparation and a dietary supplement.
[0008] Furthermore, the number of viable bacteria in the bacterial powder preparation and dietary supplement is 1.5×10 8 -5×10 8 CFU / g.
[0009] Further, including:
[0010] 1) The abundance of B. pseudolongum increased;
[0011] 2) The abundance of the dominant species, Streptococcus, increased.
[0012] The present invention also provides the use of Bifidobacterium pseudolongum in preparing a composition for treating intestinal inflammation, which is used for preparing a composition for treating intestinal flora imbalance. The composition includes a fermented product, a bacterial powder preparation and a dietary supplement.
[0013] Furthermore, the number of viable bacteria in the bacterial powder preparation and dietary supplement is 1×10 8 -5×10 8 CFU / g.
[0014] Further, including:
[0015] 1) Alleviate intestinal pathological symptoms and relieve intestinal damage;
[0016] 2) The expression of inflammatory factors decreased, while the expression of anti-inflammatory factors increased;
[0017] 3) The expression of E-cadherin, Occlindin, ZO-1, ZO-2, and ZEB decreased, alleviating the tight junction damage in the small intestine;
[0018] 4) The expression of GRP78, IRE1, PERK, ATF6, and CHOP decreased, alleviating endoplasmic reticulum stress in the small intestine;
[0019] 5) The expression of CaM, MLC, MLCK, RhoA, and ROCK decreased, alleviating the abnormal contraction of small intestinal smooth muscle;
[0020] 6) The expression of intestinal cell necrosis and apoptosis genes decreases, alleviating intestinal cell death.
[0021] The advantages and positive effects of the use of the pseudo-Bifidobacterium longum described in the present invention in the preparation of a composition for treating intestinal flora imbalance or intestinal inflammation are:
[0022] The pseudo-Bifidobacterium longum in the present application can regulate the balance of intestinal flora, alleviate intestinal pathological symptoms, and relieve intestinal inflammation, and can be widely used in the preparation of a composition for treating intestinal flora imbalance or intestinal inflammation.
[0023] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 A flowchart of model construction in an embodiment of the present invention;
[0025] Figure 2 : The effect of Bifidobacterium pseudolongum on the pathological changes of DSS-induced intestinal inflammation in the embodiment of the present invention, wherein A is the HE pathological anatomy of the small intestine; B is the comparison diagram of the length of the small intestine; C is the defecation of mice; D is the feces of mice; E is the weight record of mice; F is the DAI disease activity index of mice;
[0026] Figure 3 : The species and proportion of the mouse intestinal flora in the embodiment of the present invention, wherein A is the relative abundance histogram of sample species (top 10, gate); B is the relative abundance histogram of grouped species (top 10, gate); C is the relative abundance histogram of sample species (top 10, genus); D is the relative abundance histogram of grouped species (top 10, genus); E is the relative abundance bar graph of sample species (top 10, species); F is the relative abundance bar graph of grouped species (top 10, species);
[0027] Figure 4 : This is the diversity and abundance analysis of the small intestinal contents of each group in the embodiment of the present invention, where A is a species accumulation box plot, the horizontal axis represents the sample size, and the vertical axis represents the number of OTUs after sampling; B is the Alpha diversity index of the fecal samples of each group of mice; C is the dimensionality reduction analysis of the intestinal microorganisms of each group of mice;
[0028] Figure 5 Species difference analysis and species labeling in the embodiment of the present invention, wherein A is a genus-level phylogenetic tree; B is a LDA value distribution histogram; C is a LEfSe evolutionary branch diagram;
[0029] Figure 6 The signal pathway function prediction in the embodiment of the present invention, wherein A is the predicted KEGG secondary functional pathway; B is the relative horizontal clustering heat map of the secondary function, the vertical direction is the sample information, and the horizontal direction is the functional annotation information;
[0030] Figure 7 : The effect of Bifidobacterium pseudolongum on small intestinal inflammation in the embodiment of the present invention, wherein A is a heat map of the relative expression of mRNA of small intestinal inflammation in mice, and B is the expression level of IL-1β, IL-6, IL-10 and tumor necrosis factor TNF-α;
[0031] Figure 8 : The effect of Bifidobacterium pseudolongum on small intestinal tight junction damage in the examples of the present invention, wherein A is a heat map of the relative expression of tight junction mRNA in the small intestine of mice, B is the Western blot detection of E-cadherin, ZEB, and ZO-1, and C is the protein expression of E-cadherin, ZEB, and ZO-1 in the mouse model treated with BP and DSS;
[0032] Fig. 9 : The effect of Bifidobacterium pseudolongum on intestinal endoplasmic reticulum stress in the embodiments of the present invention, wherein A is a heat map of the relative expression of ERS mRNA in the small intestine of mice, B is Western blot detection of GRP78, IRE1, PERK, ATF6, EIF2α, xBP1, ATF4, CHOP, and C is the protein expression of GRP78, PERK, ATF6, IRE1, and CHOP in BP and DSS-treated mouse models;
[0033] Fig.10 : The effect of Bifidobacterium pseudolongum on smooth muscle contraction in DSS model mice in the embodiment of the present invention, wherein A is a heat map of relative expression of mRNA for smooth muscle contraction in small intestine of mice, B is Western blot detection of p-MLC, RHOA, and ROCK, and C is protein expression of p-MLC, RHOA, and ROCK in mouse models treated with BP and DSS;
[0034] Fig.11The figure shows the effect of Bifidobacterium pseudolongum on cell death in DSS model mice in the embodiments of the present invention, wherein A is a heat map of relative expression of mRNA for cell death in the small intestine of mice, B is Western blot detection of Caspase8, p-RIPK1, p-RIPK3, p-MLKL, Bax, Bcl-2, Caspase12, Caspase9, and Caspase3, and CK is the protein expression of Caspase8 (C), p-RIPK1 (D), p-RIPK3 (E), p-MLKL (F), Bax (G), Bcl-2 (H), Caspase12 (I), Caspase9 (J), and Caspase3 (K) in BP and DSS treated mouse models. DETAILED DESCRIPTION
[0035] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.
[0036] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.
[0037] Unless otherwise defined, the instruments and reagents used in the present invention are commercially available.
[0038] The strain of Bifidobacterium pseudolongum was purchased from Ningbo Mingzhou Biotechnology Co., Ltd.
[0039] Example 1 Strain culture
[0040] Cultivation of Bifidobacterium pseudolongum (BP):
[0041] Take out the freeze-dried Bifidobacterium pseudolongum strains stored in a 4°C refrigerator and place them in a sterilized clean bench. Take 0.5mL of liquid culture medium and add it to the freeze-dried tube, and make sure that the freeze-dried Bifidobacterium pseudolongum strains are fully dissolved. Then, take 0.4mL of the bacterial suspension and evenly transplant it into the anaerobically treated liquid culture medium. After inoculation, culture it in an anaerobic environment at 37°C for 48 hours. After 48 hours of culture, transfer it to anaerobically treated liquid culture medium and place it in an incubator at 37°C in an anaerobic environment for continued culture.
[0042] Example 2 Construction of animal model
[0043] The animal models constructed are as follows Figure 1 As shown, 40 mice aged 4-5 weeks were selected and randomly divided into four groups, with 10 mice in each group.
[0044] Normal group (C): 10 mice were fed with normal mouse chow and normal water;
[0045] BP and DSS combined treatment group (BP+DSS): 10 mice were gavaged with 1×10 8 CFU / mL of Bifidobacterium pseudolongum and fed with normal mouse food, and 24 h after gavage, normal drinking water was replaced with 5% DSS;
[0046] DSS treatment group (DSS): 5% DSS was used to replace the drinking water of 10 mice. The mice were allowed to eat and drink freely. After feeding the mice at room temperature for 7 days, the mice were euthanized with 100 mg / kg sodium pentobarbital, and the samples were quickly taken and stored in a -80°C refrigerator. This animal study has been reviewed and approved by the animal institution.
[0047] Example 3 Observation Index
[0048] 1. Disease Activity Index (DAI) score
[0049] The DAI value refers to the observed weight loss rate (no weight loss is 0 points, 1-5% weight loss is 1 point, 5-10% weight loss is 2 points, 10-15% weight loss is 3 points, and weight loss >15% is 4 points), stool consistency (normal stool consistency is 0 points, thin stool is 2 points, and diarrhea is 4 points) and stool bleeding (no stool bleeding is 0 points, positive stool occult blood is 2 points, and obvious stool bleeding is 4 points). The final result is the average of these scores. The scoring is shown in Table 1:
[0050] Table 1 DAI score table
[0051]
[0052] 2. Pathological histological observation method
[0053] The small intestine tissue was cut into three 0.4 cm long slices, fixed with prepared 4% paraformaldehyde, and then trimmed, dehydrated and paraffin-embedded in xylene overnight. The small intestine was cut into 2 μm thick slices and soaked in ZGSJ (Masson A) overnight. The small intestine sections were stained with Weggett hematoxylin (Masson A and Masson B equal amounts) for 1 minute, layered with 1% acid ethanol, then stained with scarlet fuchsin solution (Masson D) for 6 minutes, layered in phosphomolybdic phospho-tungstate solution (Masson E) for 1 minute, and then directly transferred to aniline blue solution (Masson F) for staining for 2-30 seconds. Then rinse briefly in distilled water for 2-5 minutes. Finally, the sections were decolorized with anhydrous ethanol, developed with xylene, and sealed with neutral sealant. The sections were scanned with a Pannoramic250 slide scanner (3D, HITECH). Micrographs were observed. Collagen volume was observed by image analysis system software.
[0054] 3. Evaluation of the degree of apoptosis in late apoptotic cells
[0055] The TUNEL assay is a method used to detect programmed cell death (apoptosis). It is based on labeling the ends of DNA strand breaks, which is a typical feature of apoptotic cells. Prepare 0.4 cm long tissues for pre-treatment steps such as tissue sectioning, dewaxing and hydration. Fix the tissue with a 4% formaldehyde fixative to maintain the integrity of the cell structure and DNA. Treat the sample with a solution containing a surfactant such as Triton X-100 to increase its permeability. It is then necessary to wash with a solution such as PBS (phosphate buffered saline) to remove excess fixative and surfactant. Add the TUNEL reaction solution to the sample. The reaction solution usually contains terminal deoxyribonucleotidyl transferase (TdT) and dUTP labeled with a fluorophore or biotin. TdT incorporates the labeled dUTP into the ends of DNA breaks. The sample is incubated in the dark for a period of time to allow the TdT-catalyzed reaction to occur. Remove the excess TUNEL reaction solution and wash the sample with PBS. Then observe it under a microscope. Under the microscope, the DNA ends of apoptotic cells will show fluorescent signals, while non-apoptotic cells will not.
[0056] 4. Metagenomic Analysis
[0057] We collected 0.5 g of small intestinal contents from each group of mice, extracted total DNA using the SDS-CTAB method, and then tested the purity and concentration of each group of DNA by 2% agarose gel electrophoresis. The qualified DNA product was diluted to 1 ng / μL, and then PCR amplification of the V3-V4 region of the 16SrRNA gene was performed. To ensure the quality of PCR amplification, the New England Biolabs Phusion High Fidelity PCR Master Mix (containing GC buffer and High Fidelity enzyme) was used. The recovered PCR amplification products were again detected by 2% agarose gel electrophoresis, and the qualified PCR products were purified by magnetic beads. After fluorescence quantification, the PCR product concentrations were mixed in equal amounts and detected again by 2% agarose gel electrophoresis. Qiagen's gel recovery kit was used for target strip recovery. The TruSeq DNA PCR-free sample preparation kit was used for library construction. The constructed library was quantified using Qubit and Q-PCR. NovaSeq6000 was used for machine sequencing, and Qiime1 software was used to collect and analyze data.
[0058] 5. ELISA
[0059] Enzyme-linked immunosorbent assay (ELISA) is a laboratory technique commonly used to detect and quantify antigens (such as proteins) or antibodies. The basic principle of ELISA is to detect specific molecules by combining specific antibodies with enzymes. 0.1 g of tissue sample was weighed from each group and placed in pre-cooled 0.9 mL PBS for grinding and homogenization. The sample was centrifuged at 13,000 rpm for 20 min at 4 °C, and the supernatant was collected for the determination of exosomal proteins IL-6, IL-10, IL-1β, and TNF-α. Each step was carried out strictly according to the instructions of the ELISA kit.
[0060] 6. Real-time fluorescence relative quantitative analysis
[0061] To evaluate the mRNA expression level using RT-PCR, total RNA was extracted from 0.1 g of frozen intestinal tissue in a -80°C refrigerator. The concentration and purity of the RNA solution were determined by UV spectrophotometry at wavelengths of 260 nm and 280 nm. The RNA extraction process was performed according to Table 2.
[0062] Table 2 RNA extraction steps
[0063]
[0064] Then reverse transcribe into cDNA template for RT-PCR detection. The reverse transcription system is shown in Table 3.
[0065]
[0066] For each gene to be tested, a cDNA template expressing the gene and a sample cDNA were selected for PCR reaction. The reaction procedure is shown in Table 4.
[0067] Table 4 RT-PCR reaction procedure
[0068]
[0069] Each experiment was repeated 3 times, and each sample was repeated 3 times. β-actin was used as an endogenous internal standard control. Primers were purchased from Shanghai Triangle Biotechnology Co., Ltd.
[0070] 7. Protein Immunoblotting Analysis
[0071] 0.1 mg of total intestinal tissue protein was extracted from a -80°C refrigerator, and the protein concentration was determined by the BCA method. The sample was balanced and loaded into a polyacrylamide gel electrophoresis (SDS-PAGE) gel. The electrophoresis was performed for 2 hours to separate the proteins according to their size. The separated proteins were transferred from the gel to a fixed position on the NC membrane using an electric current, and the membrane was transferred at 250 mA according to the molecular weight of different proteins. In order to prevent nonspecific binding, the NC membrane was blocked with 5% skim milk for 2 hours. In order to allow the proteins on the membrane to interact with specific antibodies, we used the corresponding primary antibody to incubate overnight and washed 3 times with TBST, each time for 15 minutes. Then the secondary antibody goat anti-rabbit IgG (1:2000, Cell Signaling Technology) was added, incubated at room temperature for 1 hour, and photographed with the SHST imaging system after development.
[0072] 8. Statistical Analysis
[0073] All experiments were repeated 3 times, and the experimental data were analyzed and plotted using GraphPad Prism Version 9.0 software (GraphPad Software, San Diego, CA). SPSS22.0 statistical software was used for statistical analysis. All data are expressed as ± standard deviation (SD) measurements. The data were compared using the t-test. The significance of different standards was *p<0.05, significant difference; **p<0.01, relatively significant difference; ***p<0.001 very significant difference; ****p<0.0001 extremely significant difference.
[0074] Example 4 Results
[0075] 1. BP can alleviate intestinal pathological symptoms
[0076] The experiment found that DSS caused severe inflammatory damage to the intestine. Histological examination showed that DSS caused inflammatory infiltration of intestinal cells, damaged villus length, reduced crypt number, and tight junction disorder. BP can significantly reduce the inflammatory damage caused by DSS to the intestine ( Figure 2 Tunel fluorescence staining revealed that the green fluorescence intensity in the DSS group was significantly higher than that in the BP+DSS group ( Figure 2 B). It was also observed that BP could alleviate the bloody stool, loose stool and weight loss caused by DSS in mice. BP could also significantly reduce the disease index (DAI) of mice caused by DSS ( Figure 2 Moreover, BP can significantly alleviate the shortening of small intestine length caused by DSS.
[0077] 2. BP can alleviate the intestinal flora disturbance induced by DSS
[0078] The experiment found that BP can cause changes in the species composition of the intestinal flora. At the phylum level, the ratio of Firmicutes to Proteobacteria changed most significantly between the groups. Compared with the DSS group, the abundance of Fimicutes in the BP+DSS group was significantly increased, while the abundance of Proteobacteria was significantly decreased ( Figure 3 At the genus level, Lactobacillus was the most abundant in group C, Streptococcus was the most abundant in group BP+DSS, and Escherichia-Shigella was the most abundant in group DSS. Moreover, the abundance of Escherichia-Shigella was significantly reduced in group BP+DSS ( Figure 3 At the species level, the abundance of Bifidobacterium pseudolongum varied most significantly in each group, and the abundance of Bifidobacterium pseudolongum in the BP+DSS group was significantly higher than that in the other groups ( Figure 3 (E, F).
[0079] 3. BP can regulate the diversity of intestinal flora
[0080] As the number of samples increased, the number of species of intestinal flora observed also increased, and the trend of the increase in the number of samples and the increase in the number of species was very gentle, indicating that the collected intestinal flora samples were good and more conducive to the species composition analysis in this experiment ( Figure 4 A in the middle). Chao1 index was used to estimate the number of observed species, Dominance was used to calculate the dominant characteristics of certain species in the intestinal flora among each group, goods coverage was used to calculate the relationship between the number of species observed in the sample and the number of species actually present in the sample, Observed features was used to observe the biodiversity characteristics actually observed in the intestinal flora, Shannon and Shannon were used to measure and measure the species diversity in the sample, and Pielou e was used to calculate the species abundance and uniformity in the intestinal flora. It can be found that the number of species, dominant species, species abundance values and uniformity in each group are different, among which the actual observed biodiversity characteristics of the BP+DSS group and the DSS group are relatively similar. ( Figure 4 (B) PCoA analysis and NMDS analysis were performed based on weighted Unifrac distance and unweighted Unifrac distance to compare the differences in intestinal flora composition between the groups. The results showed that the difference between the BP+DSS group and the DSS group was small, and the difference between these two groups was larger than that between the C group. ( Figure 4 Middle C)
[0081] 4. Effect of BP on species differences in intestinal flora
[0082] The representative sequences of the top 100 genera were studied through the genus-level evolutionary tree. The phylum-level level is shown in the branches and fan diagrams in the figure, and the genus-level species abundance distribution information in different groups is shown in the outer bar chart ( Figure 5 A). It was found that the abundance values of Lactobacillus in Firmicutes showed the most obvious difference. LEfSe analysis can be used to study the changes in microbial communities in different ecosystems, ecological conditions or experimental conditions, and help identify microorganisms that play a key role in these differences. It can be found that the dominant species between the groups are not closely related. The dominant species in group C is Lactobacillales, the dominant species in the BP+DSS group is Streptococcus, and the dominant species in the DSS group is Escherichia Shigella ( Figure 5 (B, C).
[0083] 5. Functional prediction of intestinal flora after BP treatment
[0084] The clustering heat map of the top 35 secondary functions showed that the abundance values of species related to terpenoid and polyketide metabolism, cellular process and signal transduction, and genetic information processing were higher in group C, the abundance values of species related to lipid metabolism, xenobiotic biodegradation, and metabolism were higher in group BP+DSS, and the abundance values of species related to carbohydrate metabolism, transcription, and endocrine and metabolic disease were higher in group DSS ( Figure 6 Middle A). The abundance values of species related to membrane transport, replication and repair, and carbohydrate function occupy the top three ( Figure 6 (B).
[0085] 6.BP reduces small intestinal inflammatory damage
[0086] Compared with other groups, the mRNA levels of TNF-α, NF-κB, IKB-α, IL-6, and IL-1β in the DSS group, and the expression of IL-10 mRNA were the lowest. The level of pro-inflammatory factors in the BP+DSS group was lower than that in the DSS group, and the level of IL-10 mRNA was higher than that in the DSS group ( Figure 7 The expression levels of pro-inflammatory factors IL-6, IL-1β, and TNF-α were the highest in the DSS group, and the expression level of anti-inflammatory factor IL-10 was the lowest; compared with the DSS group, the expression levels of inflammatory factors in the BP+DSS group were decreased, and the expression levels of anti-inflammatory factors were increased ( Figure 7 (B).
[0087] 7. Bifidobacterium pseudolongum slows down the damage of tight junctions in the small intestine
[0088] Compared with the other groups, the mRNA levels of E-cadherin, Occlindin, ZO-1, ZO-2, and ZEB were the highest in the DSS group, and the levels of the related mRNAs in the BP+DSS group were lower ( Figure 8 The protein levels of E-cadherin, ZO-1, and ZEB were the highest in the DSS group; compared with the DSS group, the expression levels of related proteins in the BP+DSS group were significantly decreased ( Figure 8 (B, C).
[0089] 8. Bifidobacterium pseudolongum reduces intestinal endoplasmic reticulum stress
[0090] Compared with the other groups, the mRNA expression levels of GRP78, IRE1, PERK, ATF6 and CHOP were the highest in the DSS group; compared with the DSS group, the mRNA expression levels of GRP78, IRE1, PERK, ATF6 and CHOP were significantly decreased in the BP+DSS group ( Fig. 9 Compared with the other groups, the DSS group had the highest expression levels of GRP78, IRE1, PERK, ATF6, elF2α, xBP1, ATF4, and CHOP proteins, while the expression levels of GRP78, IRE1, PERK, ATF6, elF2α, xBP1, ATF4, and CHOP proteins decreased significantly ( Fig. 9 (B, C).
[0091] 9. Bifidobacterium pseudolongum slows down abnormal contraction of small intestinal smooth muscle
[0092] The experiment detected the gene expression of CaM, MLC, MLCK, RhoA and ROCK and the protein expression of p-MLC, RhoA and ROCK. Compared with other groups, the mRNA levels of CaM, MLC, MLCK, RhoA and ROCK in the DSS group were significantly increased. The expression of related genes in the BP+DSS group was significantly decreased ( Fig.10 Compared with the DSS group, the expression levels of p-MLC, RhoA and ROCK proteins in the BP+DSS group were significantly decreased ( Fig.10 This indicates that Bifidobacterium pseudolongum can inhibit the abnormal contraction of intestinal smooth muscle induced by DSS in mice.
[0093] 10. Bifidobacterium pseudolongum slows down the death of small intestinal cells
[0094] The experiment measured the gene expression of DSS-induced intestinal cell necrosis and apoptosis genes Caspase8, RIPK1, RIPK3, MLKL, Bax, BCl-2, CytC, Caspase12, Caspase9 and Caspase3, as well as the protein expression of Caspase8, p-RIPK1, p-RIPK3, p-MLKL, Bax, BCl-2, Caspase12, Caspase9 and Caspase3. In the DSS group, the mRNA levels of Caspase8, RIPK1, RIPK3, MLKL, Bax, CytC, Caspase12, Caspase9 and Caspase3 were the highest, and the expression levels of related genes in other groups were significantly decreased compared with the DSS group. At the same time, the expression level of Bcl-2 gene was the lowest in the DSS group, while the expression level of Bcl-2 gene in the BP+DSS group was significantly increased compared with the DSS group ( Fig.11 The protein expression levels of Caspase8, p-RIPK1, p-RIPK3, p-MLKL, Bax, Bcl-2, Caspase12, Caspase9 and Caspase3 were the highest in the DSS group, while the expression levels of related proteins in the BP+DSS group were significantly lower than those in the DSS group. The expression level of Bcl-2 protein in the DSS group was the lowest, while the Bcl-2 protein level in the BP+DSS group was significantly higher than that in the DSS group ( Fig.11 This suggests that BP can inhibit DSS-induced intestinal cell death.
[0095] Therefore, the present invention adopts the above-mentioned pseudo-Bifidobacterium longum in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation. Pseudo-Bifidobacterium longum can regulate the balance of intestinal flora, while alleviating intestinal pathological symptoms and relieving intestinal inflammation, and can be widely used in the preparation of a composition for treating intestinal dysbacteriosis or intestinal inflammation.
[0096] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. Use of Bifidobacterium pseudolongum in preparing a composition for treating intestinal flora imbalance, characterized in that: The invention is used for preparing a composition for treating intestinal flora imbalance, and the composition comprises a fermented product, a bacterial powder preparation and a dietary supplement.
2. The use according to claim 1, characterized in that: The number of viable bacteria in bacterial powder preparations and dietary supplements is 1.5×10 8 -5×10 8 CFU / g.
3. The use according to claim 1, characterized in that: include: 1) The abundance of B. pseudolongum increased; 2) The abundance of the dominant species, Streptococcus, increased.
4. Use of Bifidobacterium pseudolongum in the preparation of a composition for treating intestinal inflammation, characterized in that: The invention is used for preparing a composition for treating intestinal flora imbalance, and the composition comprises a fermented product, a bacterial powder preparation and a dietary supplement.
5. The use according to claim 4, characterized in that: The number of viable bacteria in bacterial powder preparations and dietary supplements is 1×10 8 -5×10 8 CFU / g.
6. The use according to claim 4, characterized in that: include: 1) Alleviate intestinal pathological symptoms and relieve intestinal damage; 2) The expression of inflammatory factors decreased, while the expression of anti-inflammatory factors increased; 3) The expression of E-cadherin, Occlindin, ZO-1, ZO-2, and ZEB decreased, alleviating the tight junction damage in the small intestine; 4) The expression of GRP78, IRE1, PERK, ATF6, and CHOP decreased, alleviating endoplasmic reticulum stress in the small intestine; 5) The expression of CaM, MLC, MLCK, RhoA, and ROCK decreased, alleviating the abnormal contraction of small intestinal smooth muscle; 6) The expression of intestinal cell necrosis and apoptosis genes decreases, alleviating intestinal cell death.
Citation Information
Cited By
Cryptosporidium-resistant synbiotics preparation as well as preparation method and application thereof
CN119639611A
Application of bifidobacterium pseudolongum in preparation of leukemia ATO therapy adjuvant drug
CN121513050A
